Observational studyAdvances in rheumatology (London, England)2025
AFG2B gene variants and elevated protein expression in lupus nephritis: new insights into childhood-onset systemic lupus erythematosus.
Observational study in Advances in rheumatology (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundPrevious genome-wide association studies (GWAS) have associated chronic kidney disease with AFG2B variants. The AFG2B protein is linked to key immune-regulating processes through its interaction with proteasome proteins implicated in systemic inflammation. Dysregulation of these processes is a key factor in the onset of childhood-onset systemic lupus erythematosus (cSLE). This study aimed to investigate the frequency of AFG2B gene variants and the renal expression of the AFG2B protein in cSLE.
methodsThis two-phase, cross-sectional observational study included 45 patients with cSLE from a tertiary hospital in Brazil. In the first phase, we determined the frequency of variants in the AFG2B gene using PCR followed by Sanger sequencing. In the second phase, we analyzed AFG2B protein expression via immunohistochemistry in renal biopsies from patients with lupus nephritis (LN) and analyzed two publicly available databases from the Gene Expression Omnibus (GEO)—GSE32591 and GSE127797. To compare AFG2B expression in the LN, we used renal biopsy samples from patients undergoing nephrectomy for non-renal diseases (disease-free controls). We also performed modeling and molecular dynamics of AFG2B protein variants with pathogenic potential.
resultsOne patient with cSLE (2.2%) had a missense variant in exon 5 of the AFG2B gene (c.1774 A > G); molecular dynamics studies indicated this variant (p.N592D) is more stable than the wild-type protein. Twenty-five patients (55.5%) had an intronic variant (g.12211 A > G), and one patient (2.2%) had a novel intronic variant in heterozygosity (g.13196 A > G). Kidney tissue samples from patients with cSLE exhibited significantly increased AFG2B protein expression compared to normal kidney tissues (p < 0.01). We also observed a positive correlation between AFG2B protein expression in the tubules and the urinary protein-to-creatinine ratio (UPCR) in patients with cSLE.
conclusionsAFG2B protein expression is significantly elevated in the renal tissues of patients with LN compared to that in controls. Furthermore, its expression in renal tubules correlated positively with the UPCR. These results suggest a potential role for this gene in the pathophysiology of cSLE and warrant further functional investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.